Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Altered Biodistribution of 68Ga-DOTATOC.
Dupont AC, Borrelly F, Lecomte T, Maia S, Santiago Ribeiro MJ. Dupont AC, et al. Among authors: lecomte t. Clin Nucl Med. 2021 Feb 1;46(2):164-165. doi: 10.1097/RLU.0000000000003439. Clin Nucl Med. 2021. PMID: 33234939
Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). de Mestier L, et al. Among authors: lecomte t. Dig Liver Dis. 2020 May;52(5):473-492. doi: 10.1016/j.dld.2020.02.011. Epub 2020 Mar 28. Dig Liver Dis. 2020. PMID: 32234416
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C. Smith D, et al. Among authors: lecomte t. Adv Ther. 2022 Jun;39(6):2731-2748. doi: 10.1007/s12325-022-02103-7. Epub 2022 Apr 13. Adv Ther. 2022. PMID: 35419649 Free PMC article.
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
Al Mansour L, De Mestier L, Haissaguerre M, Afchain P, Hadoux J, Lecomte T, Morland D, Cottereau AS, De Rycke O, Tlili G, Tordo J, Janier M, Deville A, Walter T. Al Mansour L, et al. Among authors: lecomte t. J Nucl Med. 2024 Feb 1;65(2):258-263. doi: 10.2967/jnumed.123.266063. J Nucl Med. 2024. PMID: 38212066
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T, Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T. Lepage C, et al. Among authors: lecomte t. Eur J Cancer. 2022 Nov;175:31-40. doi: 10.1016/j.ejca.2022.07.033. Epub 2022 Sep 7. Eur J Cancer. 2022. PMID: 36087395 Free article. Clinical Trial.
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Caulet M, et al. Among authors: lecomte t. Clin Pharmacokinet. 2016 Nov;55(11):1381-1394. doi: 10.1007/s40262-016-0406-3. Clin Pharmacokinet. 2016. PMID: 27312193 Free article.
Value of a patient-reported-outcome measure of carcinoid syndrome symptoms.
Maurel J, Guimbaud R, Lecomte T, Lièvre A, Hautefeuille V, Robinson P, Francois L, Lombard-Bohas C, Forestier J, Milot L, Subtil F, Walter T. Maurel J, et al. Among authors: lecomte t. Eur J Endocrinol. 2021 May;184(5):711-722. doi: 10.1530/EJE-20-1138. Eur J Endocrinol. 2021. PMID: 33690153
Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France.
Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P; FFCD-ANGH-GERCOR. Lombard-Bohas C, et al. Among authors: lecomte t. Neuroendocrinology. 2009;89(2):217-22. doi: 10.1159/000151562. Epub 2008 Aug 22. Neuroendocrinology. 2009. PMID: 18719344
Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians.
Landi B, Bouché O, Guimbaud R, Aparicio T, Berger A, Bonvalot S, Buecher B, Blay JY, Boustière C, Coindre JM, Emile JF, Giovannini M, Lecomte T, Le Cesne A, Monges G, Napoléon B, Palazzo L, Chayvialle JA. Landi B, et al. Among authors: lecomte t. Dig Liver Dis. 2011 Dec;43(12):935-9. doi: 10.1016/j.dld.2011.04.008. Epub 2011 May 28. Dig Liver Dis. 2011. PMID: 21621493
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Asnacios A, Manet-Lacombe S, Fein F, Dubreuil O, Landi B, Zaanan A, Bonnetain F, Taïeb J. Trouilloud I, et al. Among authors: lecomte t. Eur J Cancer. 2014 Dec;50(18):3116-24. doi: 10.1016/j.ejca.2014.09.015. Epub 2014 Oct 17. Eur J Cancer. 2014. PMID: 25454414 Clinical Trial.
387 results